Movement Alert｜CareDx Intraday Rise 8.12% in Regular Trading, Q3 Beat and Higher Full-Year Outlook Support Shares

Market Focus00:13

On November 10, CareDx recorded an Intraday Rise of 8.12% in Regular Trading, trading at $84.82/share, with turnover of $37.63 million.

The clearest catalyst was the company’s latest quarterly report and raised full-year outlook. CareDx reported Q3 adjusted EPS of $0.70 and revenue of $139.362 million, both above consensus estimates of $0.25 and $120.608 million, respectively.

The company also lifted full-year revenue guidance to $520 million-$530 million from $490 million-$500 million, above the $495.1 million consensus, while adjusted EBITDA guidance was raised to $90 million-$100 million from $66 million-$78 million. Earlier in the year, CareDx had already benefited from affirmed Medicare coverage across its transplant surveillance testing portfolio, providing additional operating support for its core transplant diagnostics business.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment